• Overall Survival(OS) [ Time Frame: 3 months or up to death ]
  OS is the duration from the date of enrollment to the date of death due to any causes.
• Progression-Free Survival(PFS) [ Time Frame: 3 months or up to death ]
  PFS is the duration from the date of enrolled into clinical trial to the date of first documentation of tumor progression.
• Disease Control Rate (DCR) [ Time Frame: 3 months or up to death ]
  DCR is the proportion of patients who had a response rate including complete remission (CR), partial remission (PR) and disease stabilization (SD) evaluated by imaging according to the irRC standard.

• Immunological Monitoring [ Time Frame: Frequencies of immune cells will be monitored at 0th, 4th, 8th and 12th week. ]
  Frequencies of immune cells such as iNKT cells, natural killer cells (NK) , regulatory T cells (Treg), myeloid-derived suppressor cells (MDSC), et al will be analyzed by flow cytometry before and after iNKT infusion.
• Adverse Events(AEs) [ Time Frame: The occurrence and severities of AEs will be recorded within 12-13 weeks after iNKT cells infusion. ]
  The severities of AEs will be divided into 5 levels according to the National Cancer Institute (NCI) Common Terminology Standard for Adverse Events (CTCAE) version 4.03.
• Alpha-fetoprotein (AFP) [ Time Frame: 3 months or up to death ]
  AFP is the best-defined tumor marker for HCC, and it is widely used in clinical settings as an adjuvant diagnostic and prognostic indicator.

• Biological: iNKT cells
  5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
  Other Name: invariant Natural Killer T cells
• Drug: Cyclophosphamide
  CTX will be administered intravenously at a dose of 750mg/m2 2 days before the first iNKT cells infusion.
  Other Name: CTX
• Drug: Human recombinated Interleukin-2
  IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
  Other Name: IL-2
• Procedure: TACE
  TACE will be conducted to all patients at 0th week and 4th week.
  Other Name: Transcatheter Arterial Chemoembolization

• Experimental: TACE+iNKT for unresectable HCC
  TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TACE will be performed at 0th and 4th week. 5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
  Interventions:

  • Biological: iNKT cells
  • Drug: Cyclophosphamide
  • Drug: Human recombinated Interleukin-2
  • Procedure: TACE
• TACE for unresectable HCC
  TACE will be conducted at 0th week and 4th week.
  Intervention: Procedure: TACE

Inclusion Criteria:

• Age 18-80 years.
• Patients with hepatocellular carcinoma (BCLC, stage C) proved by histopathology or proved by CT or MRI imaging system, relapsed after previous therapy and no effective therapies known at this time.
• Life expectancy of ≥ 12 weeks.
• WBC>3.0×10^9/L, LYMPH> 0.8×10^9/L, Hb>85g/L, PLT>50×10^9/L, Cre<1.5×the upper limit of normal value.
• iNKT>10/mL in peripheral blood mononuclear cell (PBMC).
• Able to understand and sign the informed consent.

Exclusion Criteria:

• Any uncontrolled systematic disease: hypertension, heart disease, and et al.;
• Portal vein tumor thrombus, central nervous system tumor metastasis, or combined with other tumors;
• Receiving radiochemotherapy, local therapy, or targeting drugs within 4 weeks prior to this treatment;
• Unstable immune systematic diseases or infectious diseases;
• Combined with AIDS or syphilis;
• Patients with history of stem cell or organ transplantation;
• Patients with allergic history to related drugs and immunotherapy;
• Patients with complications associated with liver diseases: moderate or severe pleural effusion, pericardial effusion, ascites, or gastrointestinal hemorrhage;
• Pregnant or lactating subjects;
• Unsuitable subjects considered by clinicians.